Cyclosporine - Generic Drug Details

What are the generic drug sources for cyclosporine and what is the scope of patent protection?

Cyclosporine is the generic ingredient in nine branded drugs marketed by Apotex, Dr Reddys Labs Sa, Ivax Sub Teva Pharms, Onesource Specialty, Qilu, Sandoz, Abbvie, Novartis, Amneal, Deva Holding As, Jiangsu Anbison, Mylan, Saptalis Pharms, Teva Pharms Usa Inc, Twi Pharms, Harrow Eye, Hikma, Padagis Us, Sun Pharm, Pharm Assoc, and Pharmobedient Cnsltg, and is included in thirty-two NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cyclosporine has three hundred and thirty-six patent family members in thirty-four countries.

There are eighteen drug master file entries for cyclosporine. Twenty suppliers are listed for this compound.

Summary for cyclosporine

International Patents:	336
US Patents:	22
Tradenames:	9
Applicants:	21
NDAs:	32
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	20
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	1,126
Patent Applications:	8,485
Drug Prices:	Drug price trends for cyclosporine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cyclosporine
What excipients (inactive ingredients) are in cyclosporine?	cyclosporine excipients list
DailyMed Link:	cyclosporine at DailyMed

See drug prices for cyclosporine

Recent Clinical Trials for cyclosporine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Baylor College of Medicine	PHASE4
University of Alabama at Birmingham	PHASE4
Harrow Inc	PHASE4

See all cyclosporine clinical trials

Pharmacology for cyclosporine

Drug Class	Calcineurin Inhibitor Immunosuppressant
Mechanism of Action	Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

Medical Subject Heading (MeSH) Categories for cyclosporine

Antifungal Agents

Antirheumatic Agents

Calcineurin Inhibitors

Dermatologic Agents

Enzyme Inhibitors

Immunosuppressive Agents

Paragraph IV (Patent) Challenges for CYCLOSPORINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RESTASIS MULTIDOSE	Ophthalmic Emulsion	cyclosporine	0.05%	050790	1	2020-01-29
RESTASIS MULTIDOSE	Ophthalmic Emulsion	cyclosporine	0.05%	050790	1	2014-01-13

US Patents and Regulatory Information for cyclosporine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VEVYE	cyclosporine	SOLUTION;OPHTHALMIC	217469-001	May 30, 2023		RX	Yes	Yes			Y
Ivax Sub Teva Pharms	CYCLOSPORINE	cyclosporine	CAPSULE;ORAL	065110-002	Mar 29, 2005	AB1	RX	No	No
Sun Pharm	CEQUA	cyclosporine	SOLUTION;OPHTHALMIC	210913-001	Aug 14, 2018		RX	Yes	Yes			Y
Onesource Specialty	CYCLOSPORINE	cyclosporine	CAPSULE;ORAL	216046-001	Aug 2, 2022	AB1	RX	No	No

Expired US Patents for cyclosporine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-003	Jul 14, 1995
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-002	Jul 14, 1995
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-001	Jul 14, 1995
Novartis	NEORAL	cyclosporine	SOLUTION;ORAL	050716-001	Jul 14, 1995

International Patents for cyclosporine

Country	Patent Number	Title	Estimated Expiration
Australia	2013305539
Canada	2914472
Canada	3050298
Denmark	2887923

Supplementary Protection Certificates for cyclosporine

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049079	201740003	Slovenia		PRODUCT NAME: CICLOSPORIN; NATIONAL AUTHORISATION NUMBER: EU/1/15/990; DATE OF NATIONAL AUTHORISATION: 20150319; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1809237	CR 2015 00030	Denmark		PRODUCT NAME: CYCLOSPORIN; REG. NO/DATE: EU/1/15/990/001-002 20150323
1809237	C300741	Netherlands		PRODUCT NAME: CICLOSPORINE (EYE DROP; REGISTRATION NO/DATE: EU/1/15/990 20150319
1809237	300741	Netherlands		PRODUCT NAME: CICLOSPORINE (EYE DROP EMULSION); REGISTRATION NO/DATE: EU/1/15/990 20150323

CycloSPORINE Market Dynamics and Financial Trajectory: Pricing, Competition, and Revenue Drivers (Generics, Indications, and Supply Chain)

Last updated: June 26, 2026

CycloSPORINE’s financial trajectory is shaped by patent-style exclusivity where it still exists for specific branded forms and strengths, ongoing share migration to generics/biosimilars where applicable, and recurring demand anchored in transplant immunosuppression and autoimmune indications. In most markets, long-running generic penetration is the dominant determinant of price and margin, while product line mix (oral solution vs capsules vs modified-release formats), country reimbursement policy, and supply reliability drive volatility.

How big is the cycloSPORINE market and what revenue trajectory should investors expect?

Direct answer: The global cycloSPORINE revenue path is typically characterized by steady volume demand with declining ex-manufacturer prices after generic entry, offset in part by life-cycle differentiation across formulations and by continued demand in transplant and chronic autoimmune settings.

CycloSPORINE spans multiple branded and generic products used across:

• Solid organ transplant prophylaxis (kidney, heart, liver, lung)
• Graft-versus-host disease (GVHD) prophylaxis and treatment (indications vary by region and formulation)
• Autoimmune disease (notably psoriasis and, regionally, other chronic inflammatory conditions depending on approved labeling)

Financial dynamics observed in the drug class

• Price compression after genericization: Once primary branded formulations face generic competition, average realized prices trend down, with the speed depending on local regulatory approval timelines and pharmacy substitution rules.
• Margin concentration in product mix: Modified-release vs immediate-release differentiation can maintain modest pricing power where substitution restrictions or prescriber preference persist.
• Reimbursement and tender effects: In many countries, immunosuppressants are subject to tendering and formulary status, which can shift market share quickly among low-cost suppliers.
• Supply chain reliability: CycloSPORINE is sensitive to manufacturing capacity constraints, container-closure and batch release timelines, and global API/finished dose supply continuity. Supply interruptions can temporarily reverse price erosion.

What market drivers sustain demand for cyclosporine despite generic pressure?

Direct answer: Demand durability comes from transplant medicine and long-treatment autoimmune use where clinicians maintain adherence to a specific formulation due to narrow exposure-response considerations.

Key demand drivers:

• Transplant volume and intensity: Transplant volumes and the standard-of-care use of calcineurin inhibitors keep cycloSPORINE consumption structurally supported.
• Chronic dosing patterns: Autoimmune indications with long-term therapy maintain baseline consumption, even as pricing declines.
• Therapeutic monitoring practice: In transplant and some autoimmune settings, routine monitoring of exposure (trough levels) supports continued clinician reliance on established dosing regimens, sometimes reducing switching frequency even when generics are available.
• Formulation-specific continuity: Clinicians may prefer a specific formulation when switching could alter exposure profiles, creating a softer substitution curve than for fully substitutable products.

What pricing and margin trends does cyclosporine face in the generic era?

Direct answer: Realized pricing usually declines over time as additional generic competitors enter, but total revenue can remain stable or decline more slowly when prescription volumes offset price erosion.

Typical pattern across cyclosporine portfolios:

• Year 0 to post-first generic entry: Price begins to compress as pharmacists substitute and wholesalers revise terms.
• Year 1 to 5 post-entry: Competitor count increases; tender prices reset; average price falls again, often more sharply in public procurement-heavy markets.
• Later-stage stability: Volume growth (where population and transplant incidence rise) can partially counterbalance pricing decline, but the drug class rarely returns to prior margin levels without differentiation.

Margin outcomes by product format:

• Immediate-release capsules/liquids: Most exposed to substitution and tends to experience faster price compression.
• Modified-release forms: Often retain pricing better due to perceived exposure consistency, though tender dynamics still drive erosion.
• Concentrations and pack sizes: Can influence substitution speed and pharmacy stocking behavior.

How do generics and market entry timing affect cycloSPORINE financial performance?

Direct answer: The largest revenue inflection points occur at generic approvals and launches, followed by procurement-driven share migrations.

Market entry mechanisms:

• Regulatory approvals for abbreviated applications (jurisdiction-specific) enable generic distribution once reliance or exclusivity barriers clear.
• Automatic substitution and pharmacy switching policies accelerate share shifts.
• Tender cycles can rebase market share abruptly, shifting volumes to the lowest-cost supplier even if clinical preference exists.

What to watch for in financial reporting:

• Sequential revenue changes around tender wins and contract renewals.
• Gross-to-net pressure in markets with aggressive discounting and rebate structures.
• Inventory and allocation events during supply tightness that can temporarily elevate revenue but harm future fill rates.

Which cycloSPORINE brands and formulations drive different financial outcomes?

Direct answer: Financial outcomes split along formulation and brand history, with modified-release and pharmacy-preferred products typically maintaining better pricing and share longer.

Common cycloSPORINE product groupings:

• Oral solution
• Hard capsules
• Concentrated formulations requiring specific dosing conversions
• Modified-release capsules (where marketed and approved)

From a business planning standpoint, revenue resilience usually concentrates in:

• Products with fewer equivalent substitution hurdles
• Markets with restrictive formularies or stronger clinician adherence to specific formulations
• Countries where reimbursement limits force continued coverage of legacy strengths and packs

What competitive landscape shapes cycloSPORINE revenues across major geographies?

Direct answer: Competition is dominated by multinational generic manufacturers and local incumbents. Geography determines the speed of substitution and the degree of tender-driven price collapse.

High-level competitive patterns:

• US: Multiple generic entrants have historically compressed prices; brand remaining is typically limited by generic competition and payer behavior.
• EU/UK: Country-level tendering and national reimbursement structures control realized pricing. Stocking and prescribing rules can slow or accelerate share migration.
• Emerging markets: Price sensitivity and regulatory throughput often reduce pricing later but with significant volatility due to supplier availability.

Key competitive levers:

• API and finished-dose capacity
• Regulatory agility (rapid approvals and updated labels)
• Tender participation and bid aggressiveness
• Manufacturing consistency to secure preferred supplier status

How do supply constraints and manufacturing risks impact cycloSPORINE earnings?

Direct answer: CycloSPORINE earnings react to supply availability through allocation, backorders, and the ability to meet tender schedules.

Supply-driven effects:

• Shortages: Can elevate net pricing temporarily, but can also damage channel trust and disrupt hospital switching patterns.
• Overhang: When demand softens or procurement terms shift, inventory can create working-capital pressure.
• Batch release delays: Bioequivalence and stability-related release requirements can cause shipment lags that reduce reported revenue in a given quarter.

Financial indicators to monitor:

• Distributor lead-time changes
• Case-fill rates and order backlog trends
• Changes in gross-to-net ratio tied to emergency pricing behavior

What does cycloSPORINE exposure-response mean for switching and generic substitution?

Direct answer: CycloSPORINE’s clinical practice uses therapeutic drug monitoring, and switching between formulations can affect observed exposure, which tends to slow switching in transplant cohorts.

Business implication:

• Even in genericized markets, uptake can be slower in high-acuity transplant centers where clinicians maintain tighter controls.
• Switching still occurs when forced by payer policies or supply, but adoption curves can be less steep than for drugs without routine monitoring.

How does cycloSPORINE compare with tacrolimus and other calcineurin inhibitors on market economics?

Direct answer: Tacrolimus tends to hold share in many transplant protocols, but cycloSPORINE retains entrenched use where clinicians select calcineurin inhibitor options based on tolerability, experience, and monitoring practices. Market economics then follow protocol preferences and switching behavior.

Comparative dynamics:

• Clinical standard-of-care selection can shift between calcineurin inhibitors by region and time period.
• Payer formulary decisions can accelerate conversion to one class member.
• Side-effect profiles influence long-term adherence and clinic preferences.

Net result for cycloSPORINE:

• Price erosion from generics is usually the dominant headwind.
• Protocol-driven substitution is a secondary but ongoing pressure affecting volume.

What regulatory and reimbursement factors drive cycloSPORINE profitability?

Direct answer: Reimbursement status and tender frameworks control realized prices and volumes. In many systems, immunosuppressants face strict budget controls.

Key reimbursement levers:

• Formulary inclusion and tier placement
• Reference pricing and automatic substitution rules
• Tender-based procurement contracts
• Therapeutic interchange policies that may permit substitution across generic manufacturers
• Hospital budgeting constraints affecting procurement timing

Profitability sensitivity:

• Realized price depends less on list price and more on procurement outcomes and rebate structures.
• Managed care and procurement can reallocate volumes quickly among competing suppliers.

Key takeaways

• CycloSPORINE’s revenue trajectory is dominated by generic penetration and tender-driven price compression, with volume durability supported by transplantation and chronic autoimmune demand.
• Modified-release or formulation-specific continuity can slow substitution and preserve pricing longer than immediate-release products, but tender dynamics usually still reset economics.
• Supply chain reliability and manufacturing continuity materially affect quarter-to-quarter revenue through allocation, backorders, and tender fulfillment.
• Cross-protocol substitution within calcineurin inhibitors (notably against tacrolimus) is a continuing competitive factor, typically smaller than generic pricing pressure but relevant to volume planning.

FAQs

1. Why does cycloSPORINE sometimes retain share after generic entry?
   Routine therapeutic drug monitoring and formulation continuity in transplant cohorts can slow switching even when multiple generic products exist.

2. Do tenders in Europe typically lower cycloSPORINE prices faster than other channels?
   Yes. Hospital and national procurement cycles can rebase pricing quickly and shift volume to the lowest-cost supplier.

3. What formulation mix most influences cycloSPORINE gross margin?
   Modified-release vs immediate-release mix, concentration/pack preferences, and market-specific substitution rates typically drive realized margin differences.

4. How do supply disruptions change short-term cycloSPORINE financial results?
   Shortages can temporarily increase revenue via allocation-driven pricing and constrained supply, but they can also lead to lost contracts and damaged future fill rates.

5. Which patient populations are most resilient to cycloSPORINE brand-to-generic switching?
   High-acuity transplant patients managed with tighter exposure monitoring tend to show slower switching, especially when clinicians prefer maintaining formulation consistency.

References

1. No cited sources provided.